Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$70.39

-0.46 (-0.65%)

, AZN

AstraZeneca

$42.92

-0.11 (-0.26%)

11:55
09/12/19
09/12
11:55
09/12/19
11:55

Piper Jaffray biotech analysts to hold an analyst/industry conference call

Biotech Analysts, along with a leading oncologist, discuss the evolving treatment landscape for patients with HER2+ metastaticbreast cancer and brain metastases on an Analyst/Industry conference call to be held on September 12 at 12:30 pm.

SGEN

Seattle Genetics

$70.39

-0.46 (-0.65%)

AZN

AstraZeneca

$42.92

-0.11 (-0.26%)

PBYI

Puma Biotechnology

$11.51

-0.37 (-3.11%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$89.02

0.02 (0.02%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

  • 12

    Sep

  • 12

    Sep

  • 15

    Sep

  • 16

    Sep

  • 19

    Sep

  • 25

    Sep

  • 27

    Sep

  • 02

    Oct

  • 04

    Nov

SGEN Seattle Genetics
$70.39

-0.46 (-0.65%)

09/12/19
09/12/19
UPGRADE
Target $82

Outperform
Seattle Genetics upgraded to Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Silvan Tuerkcan upgraded Seattle Genetics to Outperform from Perform based on his review of pipeline assets Enfortumab Vedotin and tucatinib that focus on less competitive later lines of treatment with strong data. The analyst also notes that recent weakness in the shares presents an attractive entry point ahead of several pipeline catalysts. Tuerkcan raised his price target on the stock to $82 from $77.
09/12/19
OPCO
09/12/19
UPGRADE
OPCO
Outperform
Seattle Genetics upgraded to Outperform from Perform at Oppenheimer
08/26/19
BTIG
08/26/19
INITIATION
BTIG
Neutral
Seattle Genetics initiated with a Neutral at BTIG
BTIG analyst Thomas Shrader initiated Seattle Genetics with a Neutral rating. The analyst is positive on the company's antibody drug conjugate, or ADC, leadership and its efforts to broaden that label in Hodgkin lymphoma, but warns that its next growth leg for the new generation of ADCs will involve in diseases that are "much tougher" to treat and come against greater competition. Shrader also believes that much of the good news for Seattle Genetics has been priced into the stock.
07/18/19
DBAB
07/18/19
INITIATION
Target $79
DBAB
Hold
Seattle Genetics initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Konstantinos Aprilakis started Seattle Genetics with a Hold rating and $79 price target. The analyst initiated coverage on eight smid-cap Biotechnology stocks in the oncology space.
AZN AstraZeneca
$42.92

-0.11 (-0.26%)

08/14/19
ARGS
08/14/19
NO CHANGE
Target $50
ARGS
Buy
AstraZeneca price target raised to $50 from $46 at Argus
Argus analyst John Eade raised his price target on AstraZeneca to $50 and kept his Buy rating, saying the stock has outperformed over the past quarter thanks to the pipeline developments that are returning the company to growth. The analyst notes that the company's future growth should be driven by its checkpoint inhibitor Imfinzi, and he sees the program tracking toward a billion-dollar blockbuster status from $338M reported in Q2. Eade further notes that AstraZeneca management has made efforts to address the ongoing pricing pressure and generic threats to its former blockbusters Nexium and Crestor by reducing costs and assembling a new drug pipeline.
09/03/19
DZBN
09/03/19
DOWNGRADE
DZBN
Sell
AstraZeneca downgraded to Sell from Hold at DZ Bank
DZ Bank analyst Elmar Kraus downgraded AstraZeneca to Sell from Hold with a price target of 66 pounds.
09/03/19
09/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Boston Beer (SAM) downgraded to Underperform from Hold at Jefferies with analyst Kevin Grundy saying his consumer survey and web scrapes point to the potential for greater competitive intensity in the "rapidly growing" spiked seltzer category. He views Boston Beer's valuation as "stretched" given its competitive risk in hard seltzers. 2. Spirit Airlines (SAVE) downgraded to Outperform from Strong Buy at Raymond James with analyst Savanthi Syth now expecting a delay in the inflection of sentiment to early 2020. 3. AstraZeneca (AZN) downgraded to Sell from Hold at DZ Bank. 4. Heico (HEI) downgraded to Sell from Neutral at UBS with analyst Louis Raffetto citing valuation. 5. Hilton (HLT) downgraded to Neutral from Outperform at Macquarie with analyst Chad Beynon saying he believes the stock's current valuation with near-peak EBITDA multiples prices in the positives while the company faces a lack of catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/19
BOFA
08/13/19
DOWNGRADE
Target $7
BOFA
Neutral
Clovis downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill Tazeen Ahmad downgraded Clovis (CLVS) to Neutral and lowered his price target to $7 from $13 after last week's release of positive topline results for its PARP inhibitor Lynparza to treat prostate cancer by the company's competitor AstraZeneca (AZN). The analyst notes that the Lynparza update alters his expectations in the prostate cancer market to assume a two-player landscape from day one, reducing his expectations for Clovis's Rubraca peak sales to $250M from $406M with peak U.S. BRCA penetration of 15%.
PBYI Puma Biotechnology
$11.51

-0.37 (-3.11%)

05/10/19
JPMS
05/10/19
NO CHANGE
Target $19
JPMS
Underweight
Puma Biotechnology price target lowered to $19 from $27 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Puma Biotechnology to $19 from $27 saying Q1 Nerlynx sales of $46M fell well below his and Street expectations. Experience suggests that" stalled launches aren't quick and/or easy to fix," Kasimov tells investors in a post-earnings research note. He reiterates an Underweight rating on Puma Biotechnology.
05/29/19
GSCO
05/29/19
NO CHANGE
Target $24
GSCO
Neutral
Puma Biotechnology price target lowered to $24 from $29 at Goldman Sachs
Goldman Sachs analyst Paul Choi lowered his price target for Puma Biotechnology to $24 from $29 price target and keeps a Neutral rating on the shares. The analyst believes a takeover of Puma is less likely since it has "struggled to execute" on the commercial launch of Nerlynx. He removed the M&A component from his valuation framework given the "erratic commercial uptake" of the drug.
08/09/19
LEHM
08/09/19
NO CHANGE
Target $9
LEHM
Underweight
Puma Biotechnology price target lowered to $9 from $21 at Barclays
Barclays analyst Gena Wang lowered her price target for Puma Biotechnology to $9 from $21 and reiterates an Underweight rating on the shares following the company's Q2 results. The analyst continues to see limited growth potential for Nerlynx in multiple indications, including extended adjuvant, metastatic breast cancer and HER2 mutated tumors.
05/10/19
SBSH
05/10/19
DOWNGRADE
Target $24
SBSH
Neutral
Puma Biotechnology downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Puma Biotechnology to Neutral from Buy and lowered his price target for the shares to $24 following the company's Q1 results.
RHHBY Roche
$0.00

(0.00%)

07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/23/19
BTIG
07/23/19
INITIATION
Target $46
BTIG
Buy
Adaptive Biotechnologies initiated with a Buy at BTIG
BTIG analyst Amanda Murphy initiated Adaptive Biotechnologies (ADPT) with a Buy rating and a price target of $46, saying the company's "clinical immunomics database" represents its "differentiating asset" and offers "incredible value" to biopharma companies. The analyst further cites Adaptive Biotechnologies' partnership with Roche (RHHBY) that should allow it to develop new diagnostics for early detection of diseases where antigens are unknown and also its "strategic" deal with Microsoft (MSFT), whose machine learning capabilities support its immune medicine platform.
07/23/19
JPMS
07/23/19
NO CHANGE
JPMS
Neutral
Competition questions for Biogen, Ions' Spinraza not dissipating soon, says JPMorgan
Following Biogen's (BIIB) quarterly results, JPMorgan analyst Jessica Fye notes that while there seems to be limited second quarter impact to the company's and partner Ions Pharmaceuticals' (IONS) Spinraza from Novartis' (NVS) Zolgensma international revenues were down quarter over quarter for a variety of reasons despite double-digit patient growth. Overall, the analyst maintains her view that Roche (RHHBY) and PTC Therapeutics' (PTCT) Risdiplam represents a key potential competitive threat to Spinraza given the convenience of oral dosing and with filing for Risdiplam anticipated in the second half of 2019, in addition to Zolgensma's launch, Fye does not see questions related to competition for Spinraza dissipating anytime soon. The analyst reiterates a Neutral rating on Ions Pharmaceuticals' shares.
07/26/19
UBSW
07/26/19
UPGRADE
UBSW
Buy
Roche upgraded to Buy from Neutral at UBS
UBS analyst Michael Leuchten upgraded Roche to Buy from Neutral and raised his price target for the shares to CHF 300 from CHF 270. The company's legacy portfolio, built around Herceptin and Rituxan, is showing greater resilience while its "credible" neuroscience pipeline is taking shape, Leuchten tells investors in a research note. As such, he now sees Roche's business model as less challenged.
NVS Novartis
$89.02

0.02 (0.02%)

09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
08/10/19
PIPR
08/10/19
NO CHANGE
Target $210
PIPR
Overweight
Amgen wins 'big' in courtroom, Enbrel overhang removed, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond reiterates an Overweight rating and a $210 price target on Amgen's (AMGN) shares following news that the company has won the Enbrel IP litigation with challenger Sandoz. The analyst notes that this challenge could have pulled forward Enbrel's LOE from 2029 to essentially right now, which has been the number 1 concern surrounding the stock. With shares up about 6% on this news, Raymond sees the reaction as appropriate and, while the stock is approaching his target at these levels, he believes shares are likely to grind higher on this removed overhang. Sandoz is a division of Novartis (NVS).
08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
DSNKY Daiichi Sankyo
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

WE

We Company

$0.00

(0.00%)

, TMUS

T-Mobile

$77.93

-0.12 (-0.15%)

11:39
11/18/19
11/18
11:39
11/18/19
11:39
On The Fly
T-Mobile's Legere stepping down as CEO, but won't join WeWork »

Shares of T-Mobile (TMUS)…

WE

We Company

$0.00

(0.00%)

TMUS

T-Mobile

$77.93

-0.12 (-0.15%)

S

Sprint

$5.85

0.02 (0.34%)

VZ

Verizon

$59.40

-0.11 (-0.18%)

T

AT&T

$39.32

-0.17 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

11:37
11/18/19
11/18
11:37
11/18/19
11:37
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:37
11/18/19
11/18
11:37
11/18/19
11:37
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

WMT

Walmart

$120.41

1.52 (1.28%)

11:36
11/18/19
11/18
11:36
11/18/19
11:36
Periodicals
Three dead following shooting at Walmart in Duncan, OK, Fox 25 reports »

Officials with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$8.80

0.04 (0.46%)

11:35
11/18/19
11/18
11:35
11/18/19
11:35
Options
Cloudera put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

WMT

Walmart

$120.42

1.53 (1.29%)

11:31
11/18/19
11/18
11:31
11/18/19
11:31
Periodicals
Breaking Periodicals news story on Walmart »

At least three people…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$78.07

0.02 (0.03%)

11:27
11/18/19
11/18
11:27
11/18/19
11:27
Recommendations
T-Mobile analyst commentary  »

T-Mobile CEO transition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

LB

L Brands

$18.05

-0.03 (-0.17%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Options
L Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

ATTO

Atento

$2.83

(0.00%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Conference/Events
Atento to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MDCO

The Medicines Co.

$55.12

3.2 (6.16%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Conference/Events
The Medicines Co. to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

TMUS

T-Mobile

$78.12

0.07 (0.09%)

11:21
11/18/19
11/18
11:21
11/18/19
11:21
Recommendations
T-Mobile analyst commentary  »

Legere's departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/18/19
11/18
11:17
11/18/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/18/19
11/18
11:16
11/18/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Chair Powell met with President Trump and Treasury Secretary Mnuchin »

Chair Powell met with…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

LK

Luckin Coffee

$28.78

1.72 (6.36%)

11:09
11/18/19
11/18
11:09
11/18/19
11:09
Options
Heavy option volume in Luckin Coffee as display caffeine jitters »

Heavy option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

PTON

Peloton

$28.40

1.12 (4.11%)

11:05
11/18/19
11/18
11:05
11/18/19
11:05
Options
Peloton Interactive call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BA

Boeing

$373.21

1.66 (0.45%)

11:03
11/18/19
11/18
11:03
11/18/19
11:03
Hot Stocks
Boeing 'strongly disagrees' with OIG report conclusions about CST-100 Starliner »

In response to the Nov.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TC Energy

$51.43

0.05 (0.10%)

11:00
11/18/19
11/18
11:00
11/18/19
11:00
Conference/Events
TC Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

, SPX

S&P 500

$0.00

(0.00%)

10:53
11/18/19
11/18
10:53
11/18/19
10:53
General news
Trump says negative rates, easing discussed in 'very good' meeting with Powell »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$14.66

-0.665 (-4.34%)

10:50
11/18/19
11/18
10:50
11/18/19
10:50
Options
Bad trip for Canopy put seller after 10day 30% slide »

Bad trip for Canopy put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LTS

Ladenburg Thalmann

$3.48

(0.00%)

10:49
11/18/19
11/18
10:49
11/18/19
10:49
Downgrade
Ladenburg Thalmann rating change  »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$29.33

0.08 (0.27%)

10:45
11/18/19
11/18
10:45
11/18/19
10:45
Options
Twitter call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

10:45
11/18/19
11/18
10:45
11/18/19
10:45
General news
FX Action: USD-CAD »

FX Action: USD-CAD was…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.